Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Breast Neoplasms 1

Interventions

Specimen Handling 613pembrolizumab 583Magnetic Resonance Spectroscopy 543Carboplatin 430Cyclophosphamide 380Cisplatin 377Biopsy 366Paclitaxel 314Nivolumab 312Gemcitabine 308Radiotherapy 268Bevacizumab 230Dexamethasone 217fludarabine 205Docetaxel 190durvalumab 188venetoclax 187Oxaliplatin 187Rituximab 174Fluorouracil 174atezolizumab 169Pemetrexed 166Capecitabine 162Radiosurgery 160Doxorubicin 160Radiation 156Ipilimumab 144Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × utomilumab × 90 days × Clear all
NCT03217747 2026-05-05

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
173 enrolled 28 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT03971409 2026-04-17

InCITe

University of California, San Francisco

Phase 2 Active not recruiting
145 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05059522 2026-04-14

Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing

Pfizer

Phase 3 Active not recruiting
68 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡